Editorial
Artificial intelligence for personalized therapy
Chinese Clinical Oncology
2024;
13
(4)
:47
.
(15 August 2024)
Review Article
Interleukine-10 in ovarian cancer
Chinese Clinical Oncology
2024;
13
(4)
:48
.
(15 August 2024)
Challenges and solutions in 3D printing for oncology: a narrative review
Chinese Clinical Oncology
2024;
13
(4)
:49
.
(15 August 2024)
Functional outcomes of bony sarcoma (BS) in Adolescent and Young Adult Oncology (AYAO) patients—a scoping review
Chinese Clinical Oncology
2024;
13
(4)
:50
.
(15 August 2024)
A critical appraisal of the current landscape of resectable BRAF mutated colorectal liver metastases: a systematic review
Chinese Clinical Oncology
2024;
13
(4)
:51
.
(15 August 2024)
Current applications of ex-vivo fluorescent confocal microscope in urological practice: a systematic review of literature
Chinese Clinical Oncology
2024;
13
(4)
:52
.
(15 August 2024)
Unusual metastases to the breast from different extramammary malignancies: a multimodality imaging approach in a case series
Chinese Clinical Oncology
2024;
13
(4)
:53
.
(15 August 2024)
Advancements in artificial intelligence for robotic-assisted radical prostatectomy in men suffering from prostate cancer: results from a scoping review
Chinese Clinical Oncology
2024;
13
(4)
:54
.
(15 August 2024)
From simulation to surgery, advancements and challenges in robotic training for radical prostatectomy: a narrative review
Chinese Clinical Oncology
2024;
13
(4)
:55
.
(15 August 2024)
3D virtual models and augmented reality for radical prostatectomy: a narrative review
Chinese Clinical Oncology
2024;
13
(4)
:56
.
(15 August 2024)
Case Report
Diffuse large B-cell lymphoma with central nervous system symptoms during the maintenance therapy of acute lymphoblastic leukemia: a case report and literature review
Chinese Clinical Oncology
2024;
13
(4)
:57
.
(15 August 2024)
Editorial Commentary
Dual PD-1/PD-L1 and CTLA-4 inhibition strategies: tailoring immunotherapy for metastatic non-small cell lung cancer
Chinese Clinical Oncology
2024;
13
(4)
:58
.
(15 August 2024)
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811
Chinese Clinical Oncology
2024;
13
(4)
:59
.
(15 August 2024)
Zolbetuximab on the SPOTLIGHT—a light spot?
Chinese Clinical Oncology
2024;
13
(4)
:60
.
(15 August 2024)
The landscape of perioperative immunotherapy in non-small cell lung cancer: what have we learned from the AEGEAN trial?
Chinese Clinical Oncology
2024;
13
(4)
:61
.
(15 August 2024)
ESO-Shanghai 13: another milestone in the treatment of oligometastatic disease?
Chinese Clinical Oncology
2024;
13
(4)
:62
.
(15 August 2024)
Letter to the Editor
Accelerated aging and young-onset cancer risk!—are stressors of the PELICan hypothesis the missing link?
Chinese Clinical Oncology
2024;
13
(4)
:63
.
(15 August 2024)
Original Article
Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis
Chinese Clinical Oncology
2024;
13
(4)
:64
.
(15 August 2024)
